Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LZM012 in Moderate-to-Severe Plaque Psoriasis (Ib/II)
CTR20210854Phase 2Completed
- Sponsor
- Livzon Monoclonal Antibody
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lzm012 in plaque psoriasis, sponsored by Livzon Monoclonal Antibody. Started Apr 2021; status: completed.
02
Drugs
lzm012
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20210854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210854.